Development of a Clinically Relevant Temozolomide-Resistant Human Glioblastoma A-172 Cell Line
Background: Glioblastoma is the most aggressive and deadly form of brain cancer, with a median survival of approximately 14 months. A major factor contributing to an unfavorable prognosis is the development of resistance to temozolomide (TMZ), the current first-line chemotherapeutic drug for glioblastoma. Thus, developing reliable preclinical models of
Pajović, Milica +7 more
core +7 more sources
Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro [PDF]
, 2003 The growth rate of numerous cancer cell lines is regulated in part by actions of neuropeptides of the vasoactive intestinal peptide (VIP) family, which also includes pituitary adenylate cyclase-activating peptide (PACAP), glucagon, and peptide histidine ...
Dufès, Christine +4 more
core +4 more sources
Remission of invasive, cancer stem-like glioblastoma xenografts using lentiviral vector-mediated suicide gene therapy [PDF]
, 2009 Background: Glioblastoma is the most frequent and most malignant primary brain tumor with a poor prognosis. The translation of therapeutic strategies for glioblastoma from the experimental phase into the clinic has been limited by insufficient animal ...
Oleg Tsinkalovsky +23 more
core +2 more sources
Nanoscale Research Letters, 2018 A versatile synthetic route based on magnetic Fe3O4 nanoparticle (MNP) prefunctionalization with a phosphonic acid monolayer has been used to covalently bind the gH625 peptide on the nanoparticle surface.
C. Tudisco +11 more
doaj +1 more source
The role of the Bmi1-GSK3β pathway in glioblastoma [PDF]
, 2010 Malignant gliomas remain one of the deadliest of all cancers despite maximal therapy. They present unique challenges to therapy with a median survival of 12 months.
Korur, Serdar
core +1 more source
Novel therapeutic venues for glioblastoma: novel rising preclinical treatment opportunities [PDF]
, 2011 High grade gliomas, including anaplastic glioma WHO grade III and glioblastoma WHO IV (GBM), carry a dismal prognosis. Taking all nowadays-available therapeutics options, including radiation, chemotherapy and surgery, for GBM into consideration the ...
Siegelin, Yasemin +5 more
core +1 more source
Combinatorial strategy using protein kinase inhibitors and a cytotoxic compound for highly resistant glioblastoma cells : "in vitro studies" [PDF]
, 2007 Glioblastoma multiforme (GBM) is the most frequent and the most aggesssive malignant neoplasm of the human central nervous system (CNS), with a median survival of less than one year. These neoplasms are radio- and chemo-resistant, and are highly invasive,
Failly, Mike
core +1 more source
Inhibition of mitochondrial translation suppresses glioblastoma stem cell growth [PDF]
, 2021 Glioblastoma stem cells (GSCs) resist current glioblastoma (GBM) therapies. GSCs rely highly on oxidative phosphorylation (OXPHOS), whose function requires mitochondrial translation.
Notarangelo M. +23 more
core +1 more source
Fermented mistletoe extract as a multimodal antitumoral agent in gliomas [PDF]
, 2012 In Europe, commercially available extracts from the white-berry mistletoe (Viscum album L.) are widely used as a complementary cancer therapy. Mistletoe lectins have been identified as main active components and exhibit cytotoxic effects as well as ...
Mittelbronn, Michel Guy André +8 more
core +1 more source
ESTABLISHMENT OF HUMAN GLIOBLASTOMA MULTIFORME CELL LINE, G5A [PDF]
, 1984 A new cell line, G5A, was established from a human glioblastoma multiforme of the primary site and maintained for 25 months, subcultivated 36 times. The cloned cells showed morphologically epithelial-like patterns and loss of glial filaments.
Takuro, NAKAMURA +3 more
core +1 more source